These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 18423312)

  • 41. Use of dynamic contrast-enhanced MRI to assess the functional vascular pharmacokinetic parameters of normal human ovaries.
    Hall GH; Atkin SL; Turnbull LW
    J Reprod Med; 2002 Feb; 47(2):107-14. PubMed ID: 11883348
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Quantification of perfusion and permeability in breast tumors with a deconvolution-based analysis of second-bolus T1-DCE data.
    Makkat S; Luypaert R; Sourbron S; Stadnik T; De Mey J
    J Magn Reson Imaging; 2007 Jun; 25(6):1159-67. PubMed ID: 17520720
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Magnetic resonance of the breast: correlation between enhancement patterns and microvessel density in malignant tumors.
    Carriero A; Ambrossini R; Mattei PA; Angelucci D; Bonomo L
    J Exp Clin Cancer Res; 2002 Sep; 21(3 Suppl):83-7. PubMed ID: 12585660
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Assessment of hypoxia in human cervical carcinoma xenografts by dynamic contrast-enhanced magnetic resonance imaging.
    Ellingsen C; Egeland TA; Gulliksrud K; Gaustad JV; Mathiesen B; Rofstad EK
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):838-45. PubMed ID: 19215820
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dynamic contrast-enhanced magnetic resonance imaging of human melanoma xenografts with necrotic regions.
    Gaustad JV; Benjaminsen IC; Ruud EB; Rofstad EK
    J Magn Reson Imaging; 2007 Jul; 26(1):133-43. PubMed ID: 17659570
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dynamic contrast-enhanced magnetic resonance imaging for assessing tumor vascularity and vascular effects of targeted therapies in renal cell carcinoma.
    Rosen MA; Schnall MD
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):770s-776s. PubMed ID: 17255308
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MR pharmacokinetic modeling of the patellar cartilage differentiates normal from pathological conditions.
    Sanz R; Martí-Bonmatí L; Rodrigo JL; Moratal D
    J Magn Reson Imaging; 2008 Jan; 27(1):171-7. PubMed ID: 18022850
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions.
    Padhani AR
    J Magn Reson Imaging; 2002 Oct; 16(4):407-22. PubMed ID: 12353256
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tracer kinetics analysis of dynamic contrast-enhanced CT and MR data in patients with squamous cell carcinoma of the upper aerodigestive tract: comparison of the results.
    Bisdas S; Baghi M; Wagenblast J; Bisdas T; Thng CH; Mack MG; Koh TS; Ernemann U
    Clin Physiol Funct Imaging; 2009 Sep; 29(5):339-46. PubMed ID: 19473200
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Quantitative dynamic MRI and localisation of non-palpable prostate cancer].
    Cornud F; Beuvon F; Thévenin F; Chauveinc L; Vieillefond A; Descazeaux A; Flam T
    Prog Urol; 2009 Jun; 19(6):401-13. PubMed ID: 19467459
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dynamic contrast-enhanced MRI in head-and-neck cancer: the impact of region of interest selection on the intra- and interpatient variability of pharmacokinetic parameters.
    Craciunescu OI; Yoo DS; Cleland E; Muradyan N; Carroll MD; MacFall JR; Barboriak DP; Brizel DM
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):e345-50. PubMed ID: 21985945
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intratumor heterogeneity in blood perfusion in orthotopic human melanoma xenografts assessed by dynamic contrast-enhanced magnetic resonance imaging.
    Gaustad JV; Benjaminsen IC; Graff BA; Brurberg KG; Ruud EB; Rofstad EK
    J Magn Reson Imaging; 2005 Jun; 21(6):792-800. PubMed ID: 15906326
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative study into the robustness of compartmental modeling and model-free analysis in DCE-MRI studies.
    Roberts C; Issa B; Stone A; Jackson A; Waterton JC; Parker GJ
    J Magn Reson Imaging; 2006 Apr; 23(4):554-63. PubMed ID: 16506143
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Segmentation of dynamic contrast enhanced magnetic resonance imaging data.
    Nielsen T; Mouridsen K; Maxwell RJ; Stødkilde-Jørgensen H; Østergaard L; Horsman MR
    Acta Oncol; 2008; 47(7):1265-70. PubMed ID: 18661437
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetic parameters derived from dynamic contrast enhanced MRI of cervical cancers predict chemoradiotherapy outcome.
    Andersen EK; Hole KH; Lund KV; Sundfør K; Kristensen GB; Lyng H; Malinen E
    Radiother Oncol; 2013 Apr; 107(1):117-22. PubMed ID: 23333024
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of single- and dual-tracer pharmacokinetic modeling of dynamic contrast-enhanced MRI data using low, medium, and high molecular weight contrast agents.
    Orth RC; Bankson J; Price R; Jackson EF
    Magn Reson Med; 2007 Oct; 58(4):705-16. PubMed ID: 17899608
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Correlation between dynamic contrast-enhanced MRI and expression of microvascular density in the glioma].
    Yin D; Wang XY; Yan XB; Liao WH
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2005 Dec; 30(6):686-9. PubMed ID: 16708810
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Value of dynamic contrast-enhanced MRI and correlation with tumor angiogenesis in bladder cancer.
    Tuncbilek N; Kaplan M; Altaner S; Atakan IH; Süt N; Inci O; Demir MK
    AJR Am J Roentgenol; 2009 Apr; 192(4):949-55. PubMed ID: 19304699
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer.
    Yoshizako T; Wada A; Hayashi T; Uchida K; Sumura M; Uchida N; Kitagaki H; Igawa M
    Acta Radiol; 2008 Dec; 49(10):1207-13. PubMed ID: 19031184
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Determination of pharmacokinetic parameters in DCE MRI: Consequence of nonlinearity between contrast agent concentration and signal intensity.
    Heilmann M; Kiessling F; Enderlin M; Schad LR
    Invest Radiol; 2006 Jun; 41(6):536-43. PubMed ID: 16763473
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.